DataString Consulting Company Logo
DataString Consulting Company Logo
Sodium Phenylbutyrate Oral Powder Market
Home»Top Market Reports»Sodium Phenylbutyrate Oral Powder Market

Sodium Phenylbutyrate Oral Powder Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802083, Published - March 2025

Segmented in Patient Demographics (Paediatric, Adult, Elderly), Therapeutic Application (Rare Genetic Disorders, Liver Diseases, Neurological Conditions, Others), Distribution Channel, Formulation Type and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Sodium Phenylbutyrate Oral Powder
Market Outlook

The market, for Sodium phenylbutyrate oral powder was estimated at $873.2 million in 2024; and it is anticipated to increase to $1.2 billion by 2030 with projections indicating a growth to around $1.7 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.1% over the forecast period. The popularity of Sodium Oral Powder in today's market is due to various contributing factors. Being a treatment option for specific metabolic and urea cycle disorders has significantly influenced its rise. The growing global investment in healthcare and increased awareness of these conditions also support its continued importance in the sector. Efforts from industry players to improve access, to the drug and explore new possibilities for repurposing pharmaceutical agents are further boosting its reputation.


Sodium Phenylbutyrate Oral Powder is, primarily, a medication used in the treatment of high blood ammonia levels due to certain inherited disorders identified as urea cycle disorders. Its versatility does not only end here, as it also finds value in therapeutic areas like cancer treatment, demonstrating potent anti-tumor activities. Recent trends in individually tailored medicine and precision drugs have further buoyed the demand for this specialized oral powder.


Market Size Forecast & Key Insights

2019
$873M2024
2029
$1.6B2034

Absolute Growth Opportunity = $705M

The Sodium Phenylbutyrate Oral Powder market is projected to grow from $873.2 million in 2024 to $1.58 billion in 2034. This represents a CAGR of 6.1%, reflecting rising demand across Urea Cycle Disorders (UCD), Cancer Treatments and Maple Syrup Urine Disease (MSUD).

The Sodium Phenylbutyrate Oral Powder market is set to add $705 million between 2024 and 2034, with manufacturer targeting Liver Diseases & Neurological Conditions Therapeutic Application projected to gain a larger market share.

With Growing prevalence of urea cycle disorders, and Technological advancements in drug delivery, Sodium Phenylbutyrate Oral Powder market to expand 81% between 2024 and 2034.

Opportunities in the Sodium Phenylbutyrate Oral Powder Market

Strategic Collaborations

Collaborating with pharmaceutical companies can lead to significant growth opportunities for Sodium Phenylbutyrate Oral Powder in terms of research advancement and wider market access through enhanced marketing and distribution strategies that enable the development of new product formulations and increase overall availability of this beneficial medication, in the market.

Technological Innovations and Emerging Markets

Advancements in delivering drugs could increase the need for Sodium Phenylbutyrate Oral Powder usage in the future as pharmaceutical technology progresses refinements in how this powder is formulated and given to patients may boost its effectiveness and absorption rate leading to better treatment outcomes for individuals, in need of medical care.

Venturing into markets like developing countries in Asia and Latin America could offer a great opportunity for the growth of Sodium Phenylbutyrate Oral Powder product line. As healthcare investments rise and knowledge about treating diseases improves in these areas the need for specialized medications such, as Sodium Phenylbutyrate Oral Powder is predicted to increase in the foreseeable future.

Growth Opportunities in North America and Europe

Europe Outlook

In terms of Sodium Oral Powder consumption trends across different regions like North America and Europe show that both region's are actively involved in its use with Europe not only far behind the leading North America in this regard indicating potential growth opportunities for the region as well due to factors such as the prevalence of genetic disorders and supportive healthcare policies facilitating drug approvals which contribute significantly to market expansion in Europe as well a noticeable uptick in UCD treatment awareness, with Sodium Phenylbutyrate Oral Powder aiding consumption trends. Similar to North America's scenario is the landscape in Europe as well where numerous pharmaceutical powerhouses are always striving to expand their range of products successfully. The key to maximizing gains, in this region lies in gaining an insight into the market trends of Europe and engaging in meticulous strategic planning.

North America Outlook

The market in North America shows promising growth opportunities for Sodium Oral Powder due to factors like advanced healthcare technology infrastructure and rising awareness about Urea Cycle Disorders . The regions efficient drug regulations and a high prevalence of diseases also play significant roles in the increasing usage of Sodium Phenylbutyrate Oral Powder here amid tough competition, in the field. Several drug companies are currently in a race to enhance and diversify their range of products. This has led to increased efforts, in research and development focused around exploring the uses of Sodium Phenylbutyrate Oral Powder.

North America Outlook

The market in North America shows promising growth opportunities for Sodium Oral Powder due to factors like advanced healthcare technology infrastructure and rising awareness about Urea Cycle Disorders . The regions efficient drug regulations and a high prevalence of diseases also play significant roles in the increasing usage of Sodium Phenylbutyrate Oral Powder here amid tough competition, in the field. Several drug companies are currently in a race to enhance and diversify their range of products. This has led to increased efforts, in research and development focused around exploring the uses of Sodium Phenylbutyrate Oral Powder.

Europe Outlook

In terms of Sodium Oral Powder consumption trends across different regions like North America and Europe show that both region's are actively involved in its use with Europe not only far behind the leading North America in this regard indicating potential growth opportunities for the region as well due to factors such as the prevalence of genetic disorders and supportive healthcare policies facilitating drug approvals which contribute significantly to market expansion in Europe as well a noticeable uptick in UCD treatment awareness, with Sodium Phenylbutyrate Oral Powder aiding consumption trends. Similar to North America's scenario is the landscape in Europe as well where numerous pharmaceutical powerhouses are always striving to expand their range of products successfully. The key to maximizing gains, in this region lies in gaining an insight into the market trends of Europe and engaging in meticulous strategic planning.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, France, Japan are expected to grow at 4.0% to 5.9% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 7.0% to 8.4% CAGR

Market Analysis Chart

The market for Sodium Phenylbutyrate Oral Powder is influenced by factors that drive its growth and development significantly. Exploring these factors could lead to discovering market prospects. When it comes to what drives the market there are important aspects that contribute to the demand for Sodium Phenylbutyrate Oral Powder. One of the factors is the growing awareness worldwide and the rise, in diagnoses of urea cycle disorders, where this product stands out as an effective treatment choice.

Recent Developments and Technological Advancement

December 2024

PharmaCorp revealed a research initiative to improve how Sodium Phenylbutyrate Oral Powder is administered for better absorption, among individuals grappling with urea cycle disorders.

October 2024

HealthCo Labs completed a trial using Sodium Phenylbutyrate Oral Powder for innovative treatment methods, in neurological conditions.

July 2024

Medifusion has teamed up with Pyramid Biotech to create an enhanced edition of Sodium Oral Powder, in a user friendly single dose packet.

In the midst of progress in medical field advancements lies the remarkable rise of Sodium Phenylbutyrate Oral Powder in the market scenario today. The noteworthy benefits it brings as an element in treating rare diseases have positioned it at the forefront of the pharmaceutical sector. Whats more intriguing is its function, as a scavenger which has set new standards in addressing metabolic disorders and driving up demand significantly.

Impact of Industry Transitions on the Sodium Phenylbutyrate Oral Powder Market

As a core segment of the Pharmaceutical industry, the Sodium Phenylbutyrate Oral Powder market develops in line with broader industry shifts. Over recent years, transitions such as Growth in Rare Disease Therapeutics and Adoption in Oncology Treatment have redefined priorities across the Pharmaceutical sector, influencing how the Sodium Phenylbutyrate Oral Powder market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Growth in Rare Disease Therapeutics:

The Sodium Phenylbutyrate Oral Powder market is undergoing a change due to the increasing emphasis on treating rare diseases with this medication component used for conditions like urea cycle disorders and acute liver disease in the healthcare sector. The growing research and development focus on diseases is driving the demand, for this oral powder as it has proven effective compared to other limited therapeutic options available. The continuous change is affecting the sector and also influencing manufacturing processes and regulations as well, as the distribution of medical supplies.

2

Adoption in Oncology Treatment:

Oncology treatments are increasingly incorporating Sodium Oral Powder as a promising anticancer option being studied by researchers for its effectiveness, in the field of oncology investment opportunities.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Sodium Phenylbutyrate Oral Powder market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Growing Prevalence of Urea Cycle Disorders, and Increasing FDA Approvals and Clinical Trials

The increasing number of individuals with cycle disorders worldwide is also fueling the need for sodium phenylbutyrate oral powder medication to address these conditions effectively. These disorders are also defined by the bodys struggle to eliminate ammonia from the blood. Sodium phenylbutyrate also serves as a route for ammonia removal and plays a key role, in managing and treating these health issues successfully.
The growing number of FDA approvals for sodium oral powder and the rise in clinical trials are also significantly impacting the market dynamics. These approvals offer healthcare providers confidence in the safety and effectiveness of the medication hence encouraging its acceptance, within the field.
In the world of pharmaceuticals these days There is also a lot of buzz around ways to deliver drugs effectively. And one standout example is also sodium phenylbutyrate oral powderthatsbeen getting a lot of attention lately! Turns out this drug works better when taken in powder form by the mouth as it gets absorbed easily by the body and shows better results overall! Big pharma companies are also really putting their money into coming up with ways to deliver sodium phenylbutyrate efficiently through innovative methods. All in response to the growing demand, for this super effective oral powder medication.

Restraint: Regulatory Hurdles

Despite its function in managing urea cycle disorders the Sodium Phenylbutyrate Oral Powder is frequently subject to intense regulatory review. The approval pathways for medications of this nature differ from country to country leading to delays, in their availability worldwide. Consequently the rigorous and sometimes protracted approval procedures may hinder market expansion by establishing obstacles that restrict product dissemination. Such regulatory hurdles additionally dissuade aspiring participants from joining the industry resulting in stagnation and reduced competitiveness.

Challenge: Concerns over Side Effects

The growth of the Sodium Phenylbutyrate Oral Powder market is also influenced by worries about its side effects. Even though this compound is crucial for treating neurological disorders it could result in unwanted outcomes like digestive problems and reduced appetite resulting in patients losing weight. Therefore with the introduction of products that offer similar therapeutic benefits but with fewer side effects there might be a decrease in the demand, for Sodium Phenylbutyrate, which could affect market trends.

Supply Chain Landscape

Raw Material Procurement

Sigma Aldrich

Avantor

API Production

Cambrex

DSM

Oral Powder Formulation
Johnson & Johnson / Pfizer
Distribution & Sales
CVS Health / Walgreens
Raw Material Procurement

Sigma Aldrich

Avantor

API Production

Cambrex

DSM

Oral Powder Formulation

Johnson & Johnson

Pfizer

Distribution & Sales

CVS Health

Walgreens

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Urea Cycle Disorders Treatment
Healthcare & Pharmaceuticals
Horizon Therapeutics
Extensive research and development investment to ensure product efficiency and safety
Arginase Deficiency Management
Healthcare & Pharmaceuticals
RegenBioPharma
Focus on highly specialized medications to cater to unmet medical needs
Chemotherapy Adjuvant
Oncology
Takeda Pharmaceutical Company
Usage of rigorous clinical trials to confirm safety and efficacy of the oral powder as a supportive therapy in chemotherapy
Chronic liver disease Management
Healthcare & Pharmaceuticals
Eli Lilly and Company
Commitment to innovation and collaboration to develop solutions for hard-to-treat conditions

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Sodium Phenylbutyrate Oral Powder market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Sodium Phenylbutyrate Oral Powder in Cancer Treatments, Urea Cycle Disorders (UCD) and Maple Syrup Urine Disease (MSUD)

Cancer Treatments

Sodium Phenylbutyrate has shown promise in the field of cancer treatment with studies investigating its impact on gene expression and cell differentiation ins of cancer through oral administration of the powder form of the compound, which has proven advantageous due, to its ability to inhibit histone deacetylase activity.

Urea Cycle Disorders (UCD)

Sodium Phenylbutyrate Oral Powder is often prescribed for managing Urea Cycle Disorders a metabolic condition characterized by the deficiency of one of the six enzymes for ammonia removal in the body. This medication assists in facilitating a pathway to eliminate excess ammonia from the body effectively. Its usage in this context is crucial. has gained recognition from well known pharmaceutical companies such as Buphenyl and Ravicti due, to its established effectiveness and tolerable nature.

.

Maple Syrup Urine Disease (MSUD)

Sodium Phenylbutyrate Oral Powder is also used to treat Maple Syrup Urine Disease a serious metabolic condition that hinders the breakdown of specific amino acids in the body. This medication provides a route for getting rid of these substances effectively. The use of sodium oral powder in this context is supported by leading companies like Cycle Pharmaceuticals due, to its reliable results and reduced likelihood of mental and physical issues arising from the disease.

Sodium Phenylbutyrate Oral Powder vs.
Substitutes: Performance and Positioning Analysis

Sodium Phenylbutyrate Oral Powder surpasses alternative treatments, offering a potent, non-invasive option for managing urea cycle disorders. With its unique formulation and efficacy, it harnesses significant market potential and growth. These Alternatives specially Glycerol Phenylbutyrate Liquid has experienced a rapid growth as detailed in our latest report.

Sodium Phenylbutyrate Oral Powder
  • Glycerol Phenylbutyrate Liquid /
  • Buphenyl Tablets
    Effective in managing urea cycle disorders, Easy oral administration
    May trigger potential side effects, Not suitable for patients with liver diseases
    Increased tolerability, Reduced adverse reactions
    Limited efficacy, Higher cost

Sodium Phenylbutyrate Oral Powder vs.
Substitutes: Performance and Positioning Analysis

Sodium Phenylbutyrate Oral Powder

  • Effective in managing urea cycle disorders, Easy oral administration
  • May trigger potential side effects, Not suitable for patients with liver diseases

Glycerol Phenylbutyrate Liquid / Buphenyl Tablets

  • Increased tolerability, Reduced adverse reactions
  • Limited efficacy, Higher cost

Sodium Phenylbutyrate Oral Powder surpasses alternative treatments, offering a potent, non-invasive option for managing urea cycle disorders. With its unique formulation and efficacy, it harnesses significant market potential and growth. These Alternatives specially Glycerol Phenylbutyrate Liquid has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Sodium Phenylbutyrate Oral Powder market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Sodium Phenylbutyrate Oral Powder across Rare Genetic Disorders, Liver Diseases, and Neurological Conditions Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Horizon Therapeutics, Panacea Biotec Ltd., and Viatris Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Production, and Oral Powder Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Sodium Phenylbutyrate Oral Powder segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Sigma Aldrich, Avantor), API Production (Cambrex, DSM), and Oral Powder Formulation. Our parallel substitute analysis examines Glycerol Phenylbutyrate Liquid and Buphenyl Tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Horizon Therapeutics, Panacea Biotec Ltd., and Viatris Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Sodium Phenylbutyrate Oral Powder market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Sodium Phenylbutyrate Oral Powder Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 926 million
Revenue Forecast in 2034USD 1.58 billion
Growth RateCAGR of 6.1% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024873 million
Growth OpportunityUSD 705 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024873 million USD
Market Size 20271.04 billion USD
Market Size 20291.17 billion USD
Market Size 20301.25 billion USD
Market Size 20341.58 billion USD
Market Size 20351.67 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredPatient Demographics, Therapeutic Application, Distribution Channel, Formulation Type
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledHorizon Therapeutics, Panacea Biotec Ltd., Viatris Inc., Camber Pharmaceuticals Inc., Avrobio Inc., St. Louis Clinical Trials, Johnson & Johnson, Glenmark Pharmaceuticals, GlaxoSmithKline plc, Centurion Laboratories Private Limited, Cipla Ltd. and Par Pharmaceutical
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Sodium Phenylbutyrate Oral Powder Market Size, Opportunities & Strategic Insights, by Patient Demographics

4.1Paediatric
4.2Adult
4.3Elderly
Chapter 5

Sodium Phenylbutyrate Oral Powder Market Size, Opportunities & Strategic Insights, by Therapeutic Application

5.1Rare Genetic Disorders
5.2Liver Diseases
5.3Neurological Conditions
5.4Others
Chapter 6

Sodium Phenylbutyrate Oral Powder Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3Online Pharmacies
Chapter 7

Sodium Phenylbutyrate Oral Powder Market Size, Opportunities & Strategic Insights, by Formulation Type

7.1Prescription
7.2Over-the-counter
Chapter 8

Sodium Phenylbutyrate Oral Powder Market, by Region

8.1North America Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Sodium Phenylbutyrate Oral Powder Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Horizon Therapeutics
9.2.2Panacea Biotec Ltd.
9.2.3Viatris Inc.
9.2.4Camber Pharmaceuticals Inc.
9.2.5Avrobio Inc.
9.2.6St. Louis Clinical Trials
9.2.7Johnson & Johnson
9.2.8Glenmark Pharmaceuticals
9.2.9GlaxoSmithKline plc
9.2.10Centurion Laboratories Private Limited
9.2.11Cipla Ltd.
9.2.12Par Pharmaceutical